Senzime AB (SNZZF) Q4 2025 Earnings Highlights

James Sterling February 18, 2026 2 min read

Senzime AB (publ) (SNZZF) Q4 2025 Earnings Presentation

Senzime AB (publ) (SNZZF) conducted its Q4 2025 earnings call on February 18, 2026, at 3:00 AM EST. The session featured prepared remarks from key company executives.

Company Participants

Philip Siberg – Chief Executive Officer

Presentation by Philip Siberg, Chief Executive Officer

Good morning, everyone. It is a great pleasure to address you today. I am here to walk you through Senzime’s financial results for the fourth quarter of 2025, along with a concise overview of our performance throughout the entire year of 2025. Beginning with the full-year perspective, 2025 marked a period of sustained and accelerated business expansion. During this time, we made deliberate and consistent strides toward achieving profitability.

In terms of revenue growth, we achieved approximately 90% increase when measured in constant currencies. This performance allowed us to successfully meet our previously provided guidance, surpassing SEK 110 million in constant currency terms. Furthermore, our underlying gross margin saw a notable improvement. Operating expenses remained stable at controlled levels, while our adjusted EBITDA showed a positive progression, improving by roughly 16%.

These results underscore the strength of our core business fundamentals. We are firmly reiterating our target to attain positive cash flow sometime during 2026. This ambition will be supported by ongoing revenue growth momentum combined with rigorous cost management practices.

That provides a high-level summary of the year’s achievements. Now, let us delve deeper into the specific financial figures. Focusing specifically on the fourth quarter, it represented a robust conclusion to what was an exceptional year overall. In Q4, we more than doubled our business volume compared to the prior period. Reported revenues reached SEK 28.3 million, and when adjusted for constant currencies, this figure climbed even higher to SEK 31.2 million.

Several key drivers fueled this impressive quarterly growth. Notably, we secured additional significant hospital contracts, which expanded our market penetration. Sensor sales experienced particularly vigorous growth, contributing substantially to the top-line performance. Moreover, new clinical guidelines were introduced that further bolstered our product adoption, and I will provide more details on those shortly. An additional highlight was our exciting regulatory approval in the Japanese market, which has begun to catalyze momentum for our next-generation product lineup.

The quarter also saw the successful launch of several new products. Among these was the innovative EMGINE software suite, which I will discuss in greater depth momentarily. Regarding our installed base of TetraGraph systems, it continued to expand steadily. Throughout the full year of 2025, we shipped a total of 2,139 TetraGraph units. The majority of these shipments consisted of our advanced next-generation TetraGraph models, a significant increase from the less than 900 units shipped in the comparable prior-year period.

This shipment volume reflects the growing demand and acceptance of our technology in clinical settings worldwide. Our focus on innovation, combined with strategic market expansions, positions us well for continued success. As we move into 2026, these trends are expected to persist, driving us closer to our profitability milestones.